{
    "ticker": "JAZZ",
    "name": "Jazz Pharmaceuticals plc",
    "description": "Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs in various therapeutic areas, including sleep medicine, neuroscience, and oncology. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals operates with a mission to improve patients' lives through the development of meaningful therapies. The company's portfolio includes well-known products such as Xyrem, which is used to treat narcolepsy, and Epidiolex, a groundbreaking treatment for seizures associated with certain types of epilepsy. With a strong emphasis on research and development, Jazz invests significantly in the advancement of new therapies and has a robust pipeline of products in various stages of development. The company takes pride in its commitment to patient-centric solutions, aiming to provide healthcare professionals and patients with effective treatment options. Jazz Pharmaceuticals is also recognized for its strategic acquisitions that enhance its product offerings and expand its market presence. The company's dedication to addressing complex healthcare challenges signifies its role as a leader in the biopharmaceutical industry.",
    "industry": [
        "Pharmaceuticals",
        "Biotechnology"
    ],
    "headquarters": "Dublin, Ireland",
    "founded": "2003",
    "website": "https://www.jazzpharma.com",
    "ceo": "Bruce C. Cozadd",
    "social_media": {
        "twitter": "https://twitter.com/jazz_pharma",
        "linkedin": "https://www.linkedin.com/company/jazz-pharmaceuticals/"
    },
    "investor_relations": "https://investor.jazzpharmaceuticals.com",
    "key_executives": [
        {
            "name": "Bruce C. Cozadd",
            "position": "CEO"
        },
        {
            "name": "Matthew P. Lofgren",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Sleep Medicine",
            "products": [
                "Xyrem",
                "Sunosi"
            ]
        },
        {
            "category": "Neurology",
            "products": [
                "Epidiolex",
                "Nabiximols"
            ]
        },
        {
            "category": "Oncology",
            "products": [
                "Vyxeos",
                "Defitelio"
            ]
        }
    ],
    "seo": {
        "meta_title": "Jazz Pharmaceuticals plc | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Jazz Pharmaceuticals, a leader in biopharmaceuticals focusing on innovative treatments in sleep medicine, neuroscience, and oncology.",
        "keywords": [
            "Jazz Pharmaceuticals",
            "Biopharmaceuticals",
            "Sleep Medicine",
            "Neurology",
            "Oncology",
            "Xyrem",
            "Epidiolex"
        ]
    },
    "faq": [
        {
            "question": "What is Jazz Pharmaceuticals known for?",
            "answer": "Jazz Pharmaceuticals is known for its innovative biopharmaceutical products, particularly in sleep medicine and neurology."
        },
        {
            "question": "Who is the CEO of Jazz Pharmaceuticals?",
            "answer": "The CEO of Jazz Pharmaceuticals is Bruce C. Cozadd."
        },
        {
            "question": "Where is Jazz Pharmaceuticals headquartered?",
            "answer": "Jazz Pharmaceuticals is headquartered in Dublin, Ireland."
        },
        {
            "question": "What are Jazz Pharmaceuticals' main products?",
            "answer": "Jazz Pharmaceuticals' main products include Xyrem, Epidiolex, Vyxeos, and Sunosi."
        },
        {
            "question": "When was Jazz Pharmaceuticals founded?",
            "answer": "Jazz Pharmaceuticals was founded in 2003."
        }
    ],
    "competitors": [
        "ABBV",
        "BMY",
        "MRK",
        "GILD"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "VRTX",
        "NVS"
    ]
}